APA

Tavor S., Rahamim E., Sarid N., Rozovski U., Gibstein L., Aviv F., Kirsner I. & Naparstek E. (20130627). High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk. : Clinical lymphoma, myeloma & leukemia.

Chicago

Tavor Sigal, Rahamim Einam, Sarid Nadav, Rozovski Uri, Gibstein Lili, Aviv Freddy, Kirsner Ilya and Naparstek Elizabeth. 20130627. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk. : Clinical lymphoma, myeloma & leukemia.

Harvard

Tavor S., Rahamim E., Sarid N., Rozovski U., Gibstein L., Aviv F., Kirsner I. and Naparstek E. (20130627). High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk. : Clinical lymphoma, myeloma & leukemia.

MLA

Tavor Sigal, Rahamim Einam, Sarid Nadav, Rozovski Uri, Gibstein Lili, Aviv Freddy, Kirsner Ilya and Naparstek Elizabeth. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk. : Clinical lymphoma, myeloma & leukemia. 20130627.